# AMNIOTIC FLUID REVERSE TRIIODOTHYRONINE IN NORMAL AND HIGH RISK PREGNANCIES

A. TOLINO (\*), A. BIZZARRO (\*\*), G. DE PLACIDO (\*), A. TEDESCHI (\*), O. PARLATI (\*)

(\*) University of Naples, 2nd School of Medicine and Surgery, Obstetric and Gynecological Clinic (\*\*) University of Naples, 1st School of Medicine and Surgery, Medical Clinic

# SUMMARY

The Authors have dosed by radioimmunoassay the  $rT_3$  concentrations in the amniotic fluid of 12 normal pregnant women and of 25 women with high risk pregnancies at the same period of gestation.

The average of the rT<sub>3</sub> concentrations in the amniotic fluid of pregnant women affected by diabetes mellitus, EPH gestosis and with foetal growth retardation, are not different from those found in the control group.

In the patients affected by Rh isoimmunization, the rT<sub>3</sub> levels are remarkably higher than those found in the control group.

The rT<sub>3</sub> highest levels found in the amniotic fluid of pregnant women affected by Rh iso-immunization, could be due:

1) to a decreased transformation of  $rT_3$  in  $rT_2$  for an accentuated alteration of the sulphidril groups:

2) to a need of blocking the pathway's conversion of T<sub>4</sub> in T<sub>3</sub> (hormone with great catabolic effect) in these foetuses already presenting an accentuated catabolism for the chronic haemolitic anemy and for the severe hepatic alterations.

Triiodothyronine is not produced only by the thyroid, but particularly by the peripheral metabolism of thyroxine (T<sub>4</sub>).

In fact, it has been demonstrated that the highest percentage of T<sub>4</sub> (around 85%) is metabolized through monodeiodination (1).

By using sensible radioimmunoassay it has been possible to demonstrate that  $T_4$  is peripherally monodeiodinate not only into 3,5',3'-triiodothyronine, but also into 3,3',5'-triidothyronine (reverse  $T_3$ ).

A small part of reverse T<sub>3</sub> is produced at thyroid level too.

 $T_3$  and in particular  $rT_3$  are then metabolized, always through a mechanism of monodeiodination, into 3,5'-diiodothyronine  $(3,3'-T_2)$  and  $3',5'-T_2$ .

 $3,3'-T_2$  is then monodeiodinate into  $3'-T_1$ . Both the last compounds are finally metabolized into  $T_0$  (fig. 1).

In 1973, Sullivan has described a selective lack of T<sub>3</sub> with normal levels of blood and tissutal T<sub>4</sub>, in patients who died from various systemic diseases.

Low blood levels of  $T_3$  with normal levels of  $T_4$  are present in many other conditions; besides low blood levels of  $T_3$  and high concentrations of  $rT_3$  are contemporaneously present.

Dauforth (14) has observed a decrease in T<sub>3</sub> blood levels and an increase in rT<sub>3</sub> blood levels, in case of prolonged fasting.

Similar results were found in cases of proteinic malnutrition (7), of nervous anorexy (15), of cirrhosis of liver (5), of diabetes out of balance (17), of febrile conditions (19) and after administration of some drugs as dexamethazone (4) and propanolol (20).

Chopra ( $^{10}$ ) admits that the amniotic fluid presents low concentrations of  $T_4$  and traces of  $T_3$  and TSH not dosable by the actual RIA methods.

Chopra ( $^{10}$ ) and Burman ( $^{3}$ ) assert that  $rT_{3}$  concentrations in the foetal blood and in the amniotic fluid, are higher than those of the maternal blood; in fact this is evident in the amniotic fluid from the 15th week of gestation on.




Fig. 1. — A schematic view of a possible cascade of metabolism of T<sub>4</sub>. Dashed lines mark those areas where data on the operation of a pathway or the existance of a compound are either not available or insufficient. From Chopra I.J. - Pathways of metabolism of thyroid hormones. In: Recent progress in hormone research. Ed. Greep R.O., Acad. Press, London, 1978, p. 521.

The rT<sub>3</sub> concentration in the amniotic fluid decreases with the evolution of pregnancy; anyhow the values at the end of pregnancy are almost the double of those present in the maternal blood.

An interesting data derives from the finding that T<sub>3</sub> concentrations in the amniotic fluid are very low for the duration of pregnancy.

Recent studies (11) have demonstrated that in human, the rT<sub>3</sub> blood levels in the neonate, till the second week of life, are higher than those of the adult.

Since the rT<sub>3</sub> present in the amniotic fluid seems to be prevalently of foetal origin, and since the rT<sub>3</sub> blood levels are high even in non pregnant subjects affected by systemic diseases, we have studied the rT<sub>3</sub> behaviour in the amniotic fluid of high risk pregnant women.

# MATERIAL AND METHODS

We have examined 12 normal pregnant women between the 35th and 40th week of amenorrhea and 25 high risk pregnant women at the same period of pregnancy. The pregnancy's pathology examined included:

EPH gestosis (6 cases); Diabetes mellitus (5 cases):

Diabetes mellitus (5 cases); Foetal growth retardation (4 cases);

Erythroblastosis foetalis (10 cases).

The amniotic fluid was drawn by amniocentesis, previous echography, or in course of caesarean section.

The amniotic fluid drawn was immediately centrifugated and stored at -20 °C

The  $rT_3$  was dosed by radioimmunoassay using Biodata kits.

#### RESULTS

The rT<sub>3</sub> concentrations (average + SD) present in the amniotic fluid of the 12 women with normal pregnancy between the 32th and 40th week of amenorrhea, range between 55 and 130 ng/dl (90+4).

The  $rT_3$  values, in the patients affected by diabetes mellitus, range between 74 and 110 ng/dl (92+2).

The  $rT_3$  levels in the patients affected by EPH gestosis are between 62 and 125 ng/dl (93+4).

In the patients with foetal growth retardation the  $rT_3$  concentrations vary from 80 to 135 ng/dl (67+5).

As one can notice, the average of the  $rT_3$  concentrations in the amniotic fluid of the pregnant women belonging to the three categories, are not different from those found in the control group at the same stage of pregnancy (tab. 1; fig. 2).

In the 10 patients affected by erithroblastosis foetalis the  $rT_3$  levels in the amniotic fluid are remarkably higher than those found in the amniotic fluid of the control group (181+40) (tab. 1; fig. 2).

# DISCUSSION

The difference between the high levels of  $rT_3$  and the low ones of  $T_3$ , present in the foetal blood and in the amniotic fluid, is due both to the decreased conversion of  $T_4$  in  $T_3$  and to the increased conversion of  $T_4$  in  $rT_3$  in the foetus.

Table 1. — Levels of	reverse T3 in an	nniotic fluid (AFrT3,	) in women	with n	ormal and	high risk
pegnancies.						

Pregnancies	No. of patients	Gestational age (weeks)	AFrT <sub>3</sub> (ng/dl)
Normal pregnancy	. 12	32-40	55-130
Pregnancy toxemia and hypertensive disease .		32-40	62-125
Diabetes mellitus	. 5	32-40	74-110
Fetal growth retardation	. 4	32-40	80-135
Erythroblastosis fetalis	. 10	32-40	95-280

Wu ( $^{20}$ ) has found that liver and kidney homogenate of foetal lamb, have a lower capacity of deiodination of  $T_4$  in  $T_3$  of the foetal tissues is not due to the absence of the enzyme monodeiodinating the external ring of  $T_4$ , but is due to the alteration of the SH–sulphidril groups.

In fact, administration of substances protecting the SH groups, determines, in the foetal tissues, a capacity identical to that of adults, of converting  $T_4$  in  $T_3$ .

According to Chopra ( $^{12}$ ), the integrity of the sulphidril groups, would be also important for the conversion of the rT<sub>3</sub> in rT<sub>2</sub>.

Hence, the non availability of sulphidril groups would simultaneously reduce the  $T_3$  production and the  $rT_3$  catabolism.

 $T_3$  has a high catabolic action while  $T_4$  has a minimal catabolic power: its catabolic effects can be greatly due to its conversion in  $T_3$  in the peripheral tissues.

rT<sub>3</sub> and its metabolites have no catabolic action.

In most of the cases where the conversion of  $T_4$  in  $T_3$  is inhibited, the tissutal catabolism is superactive, this is true in the calorie deprivations, in the systemic diseases, after pharmacologic doses of dexamethasone.

This does not happen in the foetus, whose metabolism tends toward a predominant anabolism. Anyhow in all these conditions, catabolism is cleary, undesirable.

The inhibition of the  $T_4$  conversion in  $T_3$  and the  $rT_3$  increase could be a defen-

sive reaction of the organism to the undesirable catabolic action.

The rT<sub>3</sub> highest levels found by us in the amniotic fluid of pregnant women affected by Rh isoimmunization in comparison with the levels found in the amniotic fluid of normal pregnant women at the same week of gestation, could be due:

- 1) to a decreased rT<sub>3</sub> transformation in rT<sub>2</sub> for a more accentuated alteration of the sulphidril groups;
- 2) to a greater need of blocking the conversion pathway of  $T_4$  in  $T_3$  (hormone with high catabolic effect) in these foetuses having an already accentuated catabolism for the chronic haemolitic anemy and for the severe hepatic alterations.




Fig. 2. — Levels of reverse T<sub>3</sub> in amniotic fluid (AFrT<sub>3</sub>) in normal and high risk pregnancies.

## BIBLIOGRAPHY

1) Burman K. D., Dimond R. C., Wright F. D., Earll J. M., Bruton J., Wartofsky L.: J. Clin

Endocrinol. Metab., 44, 660, 1977.

2) Burman K. D., Read J., Dimond R. C., Strum D., Wright F. D., Patow W., Earll J. M., Wartofsky L.: J. Clin. Endocrinol. Metab., *43*, 1351, 1976.

- 3) Burr W. A., Griffiths R. S., Hoffenberg R.: Lancet, 2, 1277, 1975.
- 4) Chopra I. J.: J. Clin. Invest., 54, 583, 1974.
- 5) Chopra I. J.: J. Clin. Invest., 58, 32, 1976
- 6) Chopra I. J., Chopra U., Smith S. R., Reza M. Solomon D. H.: J. Clin. Endocrinol. Metab., 41, 1043, 1975.
- Chopra I. J., Crandall B. F.: N. Engl. J. Med., 293, 740, 1975.
   Chopra I. J., Sack J., Fisher D. A.: "Re-
- verse T<sub>3</sub> in the foetus and newborn". In: Fisher D. A., Burrow G. N. (eds.): "Perinatal Thyroid Physiology and Disease". Kroc Foundation Symposia Series, vol. 3, Raven Press, New York, 1975, p. 33.
- 9) Chopra I. J., Sack J., Fisher D. A.: Endocrinology, 97, 1080, 1975.
- 10) Chopra I. J., Sack J., Fisher D. A.: J. Clin. Invest., 55, 1137, 1975.
- 11) Chopra I. J., Solomon D. H., Chopra U., Wu S. Y., Fisher D. A., Nakamura Y.: "Pathways of metabolism of thyroid hor-

- mones". In: "Recent progress in hormone research". Ed. Greep R.O., Acad. Press,
- London, 1978, p. 521.
  12) Chopra I. J., Wu S. Y., Nakamura Y., Solomon D. H.: Endocrinology, 102, 1099, 1978 b.
- 13) Danforth E., Desilets E. J., Horton E. S., Sims E. A. H., Burger A. G., Braverman L. E., Vagenakis A. G., Ingbar S. H.: Clin. Res., 23, 573, 1975.

  14) Nicod P., Burger A., Staeheli V., Vallotton M. B. J. Clin. Endowing M. R. J. Clin. Endowing M. J. Clin. Endowing
- M.B.: I. Clin. Endocrinol. Metab., 42, 823,
- 15) Osathanondh R., Chopra I. J., Tulchinsky D., Umansky I.: J. Clin. Endocrinol. Metab., 46, 365, 1978.
- 16) Suda A., Chambers Jr. J., Thurston C., Pittman C.: Clin. Res., 25, 516, 1977.
- 17) Sullivan P. C. R., Bollinger J. A., Reichlin S.: J. Clin. Invest., 52, 83, 1973.
- 18) Wartofsky L., Burman K. D., Dimond R. C., Earll J. M.: "Studies on the nature of thyroidal suppression during acute falciparum Malaria: integrity of pituitary response to TRH and alterations in serum T<sub>3</sub> and reverse
- 19) Wiersinga W. M., Touber J. L.: Neth. J. Med., 19, 158, 1976.
- 20) Wu S. Y., Chopra I. J., Nakamura Y., Solomon D. H., Bennett L. R.: J. Clin. Endocrinol. Metab., 46, 691, 1978.